| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.VETIMM.2008.02.002 |
| P698 | PubMed publication ID | 18372050 |
| P2093 | author name string | S Richard | |
| C Andreoni | |||
| C Edlund Toulemonde | |||
| J C Audonnet | |||
| J M Minke | |||
| V Juillard | |||
| H El Garch | |||
| J Rehder | |||
| R Nordgren | |||
| S Dinic | |||
| P2860 | cites work | CD8+ T Cells Require Perforin To Clear West Nile Virus from Infected Neurons | Q27472780 |
| B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. | Q27473103 | ||
| Gamma Interferon Plays a Crucial Early Antiviral Role in Protection against West Nile Virus Infection | Q27473224 | ||
| Role of CD8+ T cells in control of West Nile virus infection | Q29619668 | ||
| West Nile virus: epidemiology and clinical features of an emerging epidemic in the United States | Q33992874 | ||
| Efficacy of a canarypox virus-vectored vaccine against feline leukaemia | Q34224843 | ||
| Current perspectives on control of equine influenza | Q34331431 | ||
| Innate and Adaptive Immune Responses Determine Protection against Disseminated Infection by West Nile Encephalitis Virus | Q34542855 | ||
| Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene | Q34996554 | ||
| West Nile virus: a growing concern? | Q35746093 | ||
| Innate sensing of viruses by toll-like receptors | Q35836607 | ||
| Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors | Q35851786 | ||
| Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector | Q39592790 | ||
| Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion | Q39597953 | ||
| Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice | Q40344535 | ||
| Equine interferon gamma synthesis in lymphocytes after in vivo infection and in vitro stimulation with EHV-1. | Q40420141 | ||
| Recombinant canarypox vectored West Nile virus (WNV) vaccine protects dogs and cats against a mosquito WNV challenge | Q40508538 | ||
| Efficacy of a recombinant equine influenza vaccine against challenge with an American lineage H3N8 influenza virus responsible for the 2003 outbreak in the United Kingdom | Q40511307 | ||
| Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses | Q40520267 | ||
| A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects | Q40819262 | ||
| Serological evidence of West Nile virus, Usutu virus and Sindbis virus infection of birds in the UK. | Q42978092 | ||
| Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans | Q43000500 | ||
| Recombinant canarypox vaccine-elicited CTL specific for dominant and subdominant simian immunodeficiency virus epitopes in rhesus monkeys | Q43871438 | ||
| Avipox-based simian immunodeficiency virus (SIV) vaccines elicit a high frequency of SIV-specific CD4+ and CD8+ T-cell responses in vaccinia-experienced SIVmac251-infected macaques. | Q44235177 | ||
| Reduced immune responses after vaccination with a recombinant herpes simplex virus type 1 vector in the presence of antiviral immunity | Q44546077 | ||
| Efficacy of a canarypox-vectored recombinant vaccine expressing the hemagglutinin gene of equine influenza H3N8 virus in the protection of ponies from viral challenge | Q45407642 | ||
| Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination | Q45418253 | ||
| Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing anti-vector immunity | Q45736005 | ||
| An improved plasmid DNA expression vector for direct injection into skeletal muscle | Q45878158 | ||
| Characterisation of CTL and IFN-gamma synthesis in ponies following vaccination with a NYVAC-based construct coding for EHV-1 immediate early gene, followed by challenge infection. | Q47696959 | ||
| Use of recombinant modified vaccinia Ankara viral vectors for equine influenza vaccination | Q47977838 | ||
| Dendritic cells and NK cells stimulate bystander T cell activation in response to TLR agonists through secretion of IFN-alpha beta and IFN-gamma. | Q51995307 | ||
| Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector | Q64383065 | ||
| Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination | Q72629529 | ||
| Determination of equid herpesvirus 1-specific, CD8+, cytotoxic T lymphocyte precursor frequencies in ponies | Q73043954 | ||
| P433 | issue | 3-4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | West Nile virus | Q158856 |
| Canarypox virus | Q2936179 | ||
| P304 | page(s) | 230-239 | |
| P577 | publication date | 2008-02-16 | |
| P1433 | published in | Veterinary Immunology and Immunopathology | Q7923704 |
| P1476 | title | A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse | |
| P478 | volume | 123 |
| Q40324434 | A DNA vaccine encoding the E protein of West Nile virus is protective and can be boosted by recombinant domain DIII. |
| Q35826722 | A Systematic Review of Recent Advances in Equine Influenza Vaccination |
| Q45356385 | An African horse sickness virus serotype 4 recombinant canarypox virus vaccine elicits specific cell-mediated immune responses in horses. |
| Q37123147 | An inactivated cell culture Japanese encephalitis vaccine (JE-ADVAX) formulated with delta inulin adjuvant provides robust heterologous protection against West Nile encephalitis via cross-protective memory B cells and neutralizing antibody |
| Q30390540 | Cross-clade immunity in cats vaccinated with a canarypox-vectored avian influenza vaccine. |
| Q35586830 | DNA vaccines in veterinary use. |
| Q40262604 | Domestic goose as a model for West Nile virus vaccine efficacy |
| Q30250251 | Epidemiological and clinical aspects on West Nile virus, a globally emerging pathogen. |
| Q42270906 | Humoral response and antiviral cytokine expression following vaccination of thoroughbred weanlings--a blinded comparison of commercially available vaccines |
| Q66679185 | In vitro and in silico Models to Study Mosquito-Borne Flavivirus Neuropathogenesis, Prevention, and Treatment |
| Q40642942 | Influential factors inducing suboptimal humoral response to vector-based influenza immunisation in Thoroughbred foals. |
| Q45372924 | Interventions Against West Nile Virus, Rift Valley Fever Virus, and Crimean-Congo Hemorrhagic Fever Virus: Where Are We? |
| Q40407813 | Investigation of antigen specific lymphocyte responses in healthy horses vaccinated with an inactivated West Nile virus vaccine |
| Q27469028 | Newcastle disease virus-vectored West Nile fever vaccine is immunogenic in mammals and poultry |
| Q38167939 | Novel vaccination approaches against equine alphavirus encephalitides |
| Q27490925 | PCP Consensus Sequences of Flaviviruses: Correlating Variance with Vector Competence and Disease Phenotype |
| Q37207640 | Phylogenetic analysis of three genes of Penguinpox virus corresponding to Vaccinia virus G8R (VLTF-1), A3L (P4b) and H3L reveals that it is most closely related to Turkeypox virus, Ostrichpox virus and Pigeonpox virus. |
| Q21284433 | Recent progress in West Nile virus diagnosis and vaccination |
| Q38807834 | Reverse Vaccinology: The Pathway from Genomes and Epitope Predictions to Tailored Recombinant Vaccines. |
| Q33442580 | Safety, immunogenicity and efficacy of poxvirus-based vector vaccines expressing the haemagglutinin gene of a highly pathogenic H5N1 avian influenza virus in pigs |
| Q38269151 | Technologies for the development of West Nile virus vaccines |
| Q26995905 | The evolution of poxvirus vaccines |
| Q52573695 | The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host. |
| Q93155035 | Twenty Years of Progress Toward West Nile Virus Vaccine Development |
| Q35087579 | Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge |
| Q37842337 | Vaccines and immunotherapeutics for the prevention and treatment of infections with West Nile virus |
| Q26999702 | Vaccines in development against West Nile virus |
| Q92258137 | Viral Equine Encephalitis, a Growing Threat to the Horse Population in Europe? |
| Q90228470 | Virus-Like Particle Systems for Vaccine Development against Viruses in the Flaviviridae Family |
| Q30402540 | West Nile viral infection of equids |
| Q40376589 | West Nile virus infections in children |
| Q37434776 | West Nile virus state of the art report of MALWEST Project |
| Q92215826 | West Nile virus vaccines - current situation and future directions |
| Q37876095 | West Nile virus: the complex biology of an emerging pathogen |
Search more.